Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trialResearch in context

Summary: Background: This phase II prospective trial aimed to investigate the efficacy and safety of adebrelimab (PD-L1 antibody) plus first-line chemotherapy followed by sequential thoracic radiotherapy (TRT) combined with adebrelimab in extensive-stage small–cell lung cancer (ES-SCLC). Biomarkers...

Descripció completa

Dades bibliogràfiques

Autors principals:	Dawei Chen, Bing Zou, Butuo Li, Aiqin Gao, Wei Huang, Qian Shao, Xiangjiao Meng, Pinliang Zhang, Xiaoyong Tang, Xudong Hu, Yan Zhang, Jun Guo, Changhong Zhao, Jiajia Yuan, Qian Li, Changbin Zhu, Jinming Yu, Linlin Wang
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-09-01
Col·lecció:	EClinicalMedicine
Matèries:	Adebrelimab Radiotherapy Immunotherapy Predictive biomarker ES-SCLC
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2589537024003742
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!